New treatment news for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
Senior woman with lung cancer during medical visit

FDA Grants Lorlatinib Breakthrough Designation for NSCLC: “This regulatory designation recognizes the potential for lorlatinib to provide an important treatment option for patients with ALK-positive NSCLC whose cancers have progressed despite treatment,” Mace Rothenberg, MD, chief development officer, Oncology, Pfizer Global Product Development, said in a release. “Pfizer’s rapid development of lorlatinib reflects a commitment to developing biomarker-driven therapies to meet the evolving needs of patients.”

Read more